Spahr Laurent, Giostra Emiliano, Negro Francesco, Goossens Nicolas
Service de gastroentérologie et hépatologie, Centre des affections hépato-biliaires et pancréatique, HUG, 1211 Genève 14.
Rev Med Suisse. 2020 Sep 2;16(704):1544-1547.
Non-alcoholic fatty liver disease (NAFLD) includes a spectrum of hepatic pathology ranging from non-alcoholic fatty liver, non-alcoholic steatohepatitis (NASH) occasionally complicated with hepatic fibrosis or even cirrhosis. In order to propose a diagnosis with positive criteria, a panel of experts recently proposed the use of an alternative nomenclature, metabolic-dysfunction-associated fatty liver disease (MAFLD) whose use remains debated. In addition, in Switzerland and elsewhere, there is strong epidemiological growth of NAFLD. The next years will probably see the approval of new therapies for NAFLD/NASH but, at present, management remains focused on lifestyle interventions and joint monitoring by the primary care physician and, when necessary, the specialist.
非酒精性脂肪性肝病（NAFLD）包括一系列肝脏病变，从非酒精性脂肪肝、偶尔合并肝纤维化甚至肝硬化的非酒精性脂肪性肝炎（NASH）。为了提出具有阳性标准的诊断，一组专家最近提议使用另一种命名法，即代谢功能障碍相关脂肪性肝病（MAFLD），其使用仍存在争议。此外，在瑞士和其他地方，NAFLD的流行病学增长强劲。未来几年可能会批准用于NAFLD/NASH的新疗法，但目前，管理仍侧重于生活方式干预以及由初级保健医生并在必要时由专科医生进行联合监测。
